Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 8/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26846118 | 0.80 | OGA (0.39) | ACACBPANK3MEN1KMT2AOGA | |
| SCHEMBL26845645 | 0.79 | OPRM1 (0.43) | ACACBPANK3MEN1KMT2AOGA | |
| SCHEMBL13466910 | 0.78 | PANK3 (0.40) | ACACBPANK3OGATSHRPOLB | |
| SCHEMBL19105574 | 0.78 | PANK3 (0.40) | ACACBPANK3OGAPOLB | |
| SCHEMBL7913329 | 0.77 | POLB (0.53) | ACACBKMT2ATSHRPOLB | |
| SCHEMBL16131123 | 0.77 | POLB (0.42) | ACACBPANK3MEN1KMT2AOGA | |
| SCHEMBL24827889 | 0.76 | CYP3A4 (0.36) | ACACBPANK3MEN1KMT2AOGA | |
| SCHEMBL11402241 | 0.75 | HRH4 (0.47) | PANK3KMT2AOGATSHRPOLB | |
| SCHEMBL26815219 | 0.75 | CYP3A4 (0.36) | ACACBPANK3MEN1KMT2AOGA | |
| SCHEMBL17543143 | 0.75 | MAPT (0.44) | PANK3MEN1KMT2ATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |